---
---

# 42 U.S.C., USLM ref /us/usc/t42/s290dd–3

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schIII–A/ptD/m__us_usc_t42_s290dd–2.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schIII–A/ptD/m__us_usc_t42_s290ee.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs290dd%E2%80%933)

## § 290dd–3. Grants for reducing overdose deaths

    (a) __Establishment__ 

        (1) __In general__ 

            The Secretary shall award grants to eligible entities to expand access to drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 301][/us/usc/t21/s301] et seq.\] for emergency treatment of known or suspected opioid overdose.

        (2) __Maximum grant amount__ 

            A grant awarded under this section may not be for more than $200,000 per grant year.

        (3) __Eligible entity__ 

            For purposes of this section, the term “eligible entity” means a Federally qualified health center (as defined in [section 1395x(aa) of this title][/us/usc/t42/s1395x/aa]), an opioid treatment program under part 8 of title 42, Code of Federal Regulations, any practitioner dispensing narcotic drugs pursuant to [section 823(g) of title 21][/us/usc/t21/s823/g], or any other entity that the Secretary deems appropriate.

        (4) __Prescribing__ 

        For purposes of this section, the term “prescribing” means, with respect to a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose, the practice of prescribing such drug or device—

            (A) in conjunction with an opioid prescription for patients at an elevated risk of overdose;

            (B) in conjunction with an opioid agonist approved under section 505 of the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 355][/us/usc/t21/s355]\] for the treatment of opioid use disorder;

            (C) to the caregiver or a close relative of patients at an elevated risk of overdose from opioids; or

            (D) in other circumstances in which a provider identifies a patient is at an elevated risk for an intentional or unintentional drug overdose from heroin or prescription opioid therapies.

    (b) __Application__ 

    To be eligible to receive a grant under this section, an eligible entity shall submit to the Secretary, in such form and manner as specified by the Secretary, an application that describes—

        (1) the extent to which the area to which the entity will furnish services through use of the grant is experiencing significant morbidity and mortality caused by opioid abuse;

        (2) the criteria that will be used to identify eligible patients to participate in such program; and

        (3) a plan for sustaining the program after Federal support for the program has ended.

    (c) __Use of funds__ 

    An eligible entity receiving a grant under this section may use amounts under the grant for any of the following activities, but may use not more than 20 percent of the grant funds for activities described in paragraphs (3) and (4):

        (1) To establish a program for prescribing a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 301][/us/usc/t21/s301] et seq.\] for emergency treatment of known or suspected opioid overdose.

        (2) To train and provide resources for health care providers and pharmacists on the prescribing of drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose.

        (3) To purchase drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose, for distribution under the program described in paragraph (1).

        (4) To offset the co-payments and other cost sharing associated with drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose.

        (5) To establish protocols to connect patients who have experienced a drug overdose with appropriate treatment, including medication-assisted treatment and appropriate counseling and behavioral therapies.

    (d) __Evaluations by recipients__ 

        As a condition of receipt of a grant under this section, an eligible entity shall, for each year for which the grant is received, submit to the Secretary an evaluation of activities funded by the grant which contains such information as the Secretary may reasonably require.

    (e) __Reports by the Secretary__ 

        Not later than 5 years after the date on which the first grant under this section is awarded, the Secretary shall submit to the appropriate committees of the House of Representatives and of the Senate a report aggregating the information received from the grant recipients for such year under subsection (d) and evaluating the outcomes achieved by the programs funded by grants awarded under this section.

    (f) __Authorization of appropriations__ 

        There is authorized to be appropriated to carry out this section, $5,000,000 for the period of fiscal years 2017 through 2021.

([July 1, 1944, ch. 373][/us/act/1944-07-01/ch373], title V, § 544, as added [Pub. L. 114–198, title I][/us/pl/114/198/tI], § 107(a), July 22, 2016, [130 Stat. 703][/us/stat/130/703].)

 __References in Text__ 

    The Federal Food, Drug, and Cosmetic Act, referred to in subsecs. (a)(1) and (c)(1) to (4), is [act June 25, 1938, ch. 675][/us/act/1938-06-25/ch675], [52 Stat. 1040][/us/stat/52/1040], which is classified generally to chapter 9 (§ 301 et seq.) of Title 21, Food and Drugs. For complete classification of this Act to the Code, see [section 301 of Title 21][/us/usc/t21/s301] and Tables.

 __Prior Provisions__ 

    A prior section 290dd–3, [act July 1, 1944, ch. 373, title V][/us/act/1944-07-01/ch373/tV], § 544, formerly [Pub. L. 91–616, title III][/us/pl/91/616/tIII], § 333, Dec. 31, 1970, [84 Stat. 1853][/us/stat/84/1853], as amended [Pub. L. 93–282, title I][/us/pl/93/282/tI], § 122(a), May 14, 1974, [88 Stat. 131][/us/stat/88/131]; [Pub. L. 94–581, title I][/us/pl/94/581/tI], § 111(c)(4), Oct. 21, 1976, [90 Stat. 2852][/us/stat/90/2852]; renumbered § 523 of act July 1, 1944, Apr. 26, 1983, [Pub. L. 98–24][/us/pl/98/24], § 2(b)(13), [97 Stat. 181][/us/stat/97/181]; Aug. 27, 1986, [Pub. L. 99–401, title I][/us/pl/99/401/tI], § 106(a), [100 Stat. 907][/us/stat/100/907]; renumbered § 544, July 22, 1987, [Pub. L. 100–77, title VI][/us/pl/100/77/tVI], § 611(2), [101 Stat. 516][/us/stat/101/516]; June 13, 1991, [Pub. L. 102–54][/us/pl/102/54], § 13(q)(1)(A)(ii), [105 Stat. 278][/us/stat/105/278], relating to confidentiality of patient records for alcohol abuse and alcoholism programs, was omitted in the general revision of this part by [Pub. L. 102–321][/us/pl/102/321]. See [section 290dd–2 of this title][/us/usc/t42/s290dd–2].

 __Improving Access to Overdose Treatment__ 

[Pub. L. 114–198, title I][/us/pl/114/198/tI], § 107(b), July 22, 2016, [130 Stat. 705][/us/stat/130/705], provided that:

>     “(1)  __Information on best practices__  __.—__ 

>     Not later than 180 days after the date of enactment of this Act \[July 22, 2016\]:

>         “(A) The Secretary of Health and Human Services may provide information to prescribers within Federally qualified health centers (as defined in paragraph (4) of section 1861(aa) of the Social Security Act ([42 U.S.C. 1395x(aa)][/us/usc/t42/s1395x/aa])), and the health care facilities of the Indian Health Service, on best practices for prescribing or co-prescribing a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act ([21 U.S.C. 301][/us/usc/t21/s301] et seq.) for emergency treatment of known or suspected opioid overdose, including for patients receiving chronic opioid therapy and patients being treated for opioid use disorders.

>         “(B) The Secretary of Defense may provide information to prescribers within Department of Defense medical facilities on best practices for prescribing or co-prescribing a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act ([21 U.S.C. 301][/us/usc/t21/s301] et seq.) for emergency treatment of known or suspected opioid overdose, including for patients receiving chronic opioid therapy and patients being treated for opioid use disorders.

>         “(C) The Secretary of Veterans Affairs may provide information to prescribers within Department of Veterans Affairs medical facilities on best practices for prescribing or co-prescribing a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act ([21 U.S.C. 301][/us/usc/t21/s301] et seq.) for emergency treatment of known or suspected opioid overdose, including for patients receiving chronic opioid therapy and patients being treated for opioid use disorders.

>     “(2)  __Rule of construction__  __.—__ 

>     Nothing in this subsection should be construed to establish or contribute to a medical standard of care.”

----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schIII–A/ptD/m__us_usc_t42_s290dd–2.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schIII–A/ptD/m__us_usc_t42_s290ee.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs290dd%E2%80%933)

----------
----------

[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/usc/t42/s1395x/aa]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395x%2Faa
[/us/usc/t21/s823/g]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs823%2Fg
[/us/usc/t21/s355]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/act/1944-07-01/ch373]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1944-07-01%2Fch373
[/us/pl/114/198/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F114%2F198%2FtI
[/us/stat/130/703]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F130%2F703
[/us/act/1938-06-25/ch675]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675
[/us/stat/52/1040]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F52%2F1040
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/act/1944-07-01/ch373/tV]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1944-07-01%2Fch373%2FtV
[/us/pl/91/616/tIII]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F91%2F616%2FtIII
[/us/stat/84/1853]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F84%2F1853
[/us/pl/93/282/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F93%2F282%2FtI
[/us/stat/88/131]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F88%2F131
[/us/pl/94/581/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F94%2F581%2FtI
[/us/stat/90/2852]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F90%2F2852
[/us/pl/98/24]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F98%2F24
[/us/stat/97/181]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F97%2F181
[/us/pl/99/401/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F99%2F401%2FtI
[/us/stat/100/907]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F100%2F907
[/us/pl/100/77/tVI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F100%2F77%2FtVI
[/us/stat/101/516]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F101%2F516
[/us/pl/102/54]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F54
[/us/stat/105/278]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F105%2F278
[/us/pl/102/321]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F321
[/us/usc/t42/s290dd–2]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs290dd%E2%80%932
[/us/pl/114/198/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F114%2F198%2FtI
[/us/stat/130/705]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F130%2F705
[/us/usc/t42/s1395x/aa]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395x%2Faa
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301
[/us/usc/t21/s301]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs301


